Insoma Bio, Inc., a for-profit biotechnology company, was awarded a $979,197 Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program to develop an injectable protein matrix to enhance the stability of autologous fat grafts for craniofacial reconstruction. The 2-year project aims to improve clinical outcomes for patients undergoing facial reconstructive surgery by addressing the common challenges of volume and shape loss associated with fat grafting procedures. Insoma Bio's proprietary elastin-mimetic biomaterial technology, called Fractomers, is designed to provide a moldable, biocompatible scaffold that supports fat graft survival and vascularization. The funding will support scale-up, toxicology studies, and preclinical efficacy evaluations to prepare the product for regulatory submission, clinical trials, and eventual commercialization. No subawards are planned under this award.
Generated 5/14/24, 2:05 AM